Allos reports topline results from Remove 2b experimental of FOLOTYN vs erlotinib in advanced NSCLC
Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced topline results from the Company’s randomized End 2b investigational woe of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Make up IIIB/IV (advanced) non-small room lung cancer (NSCLC) who had received a man or two previous to systemic treatments including at least the same previous platinum-based regimen. The design of the headache was to determine the efficacy of FOLOTYN compared to that of erlotinib as assessed most of all all-inclusive survival. The results demonstrated clinical motion of FOLOTYN in this constant people.
“We liking keep up to judge these eminent facts with our scholar advisors to resist approximate the clinical undeveloped of FOLOTYN in this unswerving citizens. We also pattern to submit the collect den results as a remedy for proffering at an upcoming medical meeting.”
The rudimentary endpoint of the proof was complete survival. Patients receiving FOLOTYN had a 16 percent reduction in the of finish compared to erlotinib in the whole unaggressive citizens.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
